Viking Therapeutics Concludes Broad Manufacturing Agreement With CordenPharma To Support Commercialization of VK2735

Viking Therapeutics, Inc. (NASDAQ:VKTX) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Viking Therapeutics, Inc. (NASDAQ:VKTX) and CordenPharma have concluded a multi-year manufacturing contract to facilitate the commercial production of VK2735, the company’s dual GLP-1/GIP agonist for obesity. The deal guarantees a yearly supply of more than 1 billion oral pills, 100 million autoinjectors, 100 million vial/syringe units, and several metric tons of API. Prepayments of $150 million will be made by the firm through 2028 and applied to upcoming orders. The agreement offers specific capacity for both oral and subcutaneous formulations.

Viking Therapeutics Concludes Broad Manufacturing Agreement With CordenPharma To Support Commercialization of VK2735

michaelheim/Shutterstock.com

Viking Therapeutics, Inc. (NASDAQ:VKTX)’s main metabolic therapy candidate, VK2735, is being developed as an injectable and oral medication. Phase 3 development for the injectable version is scheduled to start in Q2 2025, while the company is now completing a Phase 2 VENTURE-Oral trial. The business still owns global rights to VK2735. CEO Brian Lian noted that CordenPharma’s end-to-end supply capability and peptide production experience are essential for growing commercial demand. Viking Therapeutics, Inc. (NASDAQ:VKTX) anticipates that the product will have conventional pharmaceutical margins and have a multibillion-dollar potential. It is among the Best Weight Loss Stocks.

While we acknowledge the risk and potential of VKTX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than VKTX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025.

Disclosure. None.